中医药联合PD-1与PD-L1抑制剂在NSCLC治疗上的临床研究进展

Clinical Research Progress of Traditional Chinese Medicine Combined with PD-1 and PD-L1 Inhibitors in the Treatment of NSCLC

摘要: 肺癌是全球患者死亡的主要原因之一，其中NSCLC (非小细胞肺癌)是其主要类型，预后不良。其中，程序性死亡受体1 (PD-1)及其配体(PD-L1)作为第二代免疫检查点抑制剂的临床靶点，已成为新药研发的热点之一。目前，我国国家食品药品监督管理总局已批准多种PD-1/PD-L1单克隆抗体药物如纳武利尤单抗、帕博利珠单抗和阿替利珠单抗等上市，用于治疗小细胞肺癌等。本文综述了PD-1与PD-L1抑制剂在联合化疗及放疗治疗NSCLC患者的研究结果，并概述了目前PD-1与PD-L1抑制剂存在的缺陷以及不足，同时总结了中医药联合PD-1/PD-L1治疗的巨大潜力。

Abstract: Lung cancer is one of the main causes of death for patients worldwide. Among them, NSCLC (Non-Small Cell Lung Cancer) is the main type and has a poor prognosis. Among them, programmed death receptor 1 (PD-1) and its ligand (PD-L1), as clinical targets of the second-generation immune checkpoint inhibitors, have become one of the hotspots in new drug research and development. At present, the National Medical Products Administration of China has approved the marketing of a variety of PD-1/PD-L1 monoclonal antibody drugs such as nivolumab, pembrolizumab and atezolizumab, etc., for the treatment of small cell lung cancer, etc. This article reviews the research results of PD-1 and PD-L1 inhibitors in the combined treatment of NSCLC patients with chemotherapy and radiotherapy, outlines the existing deficiencies and shortcomings of PD-1 and PD-L1 inhibitors at present, and summarizes the great potential of traditional Chinese medicine combined with PD-1/PD-L1 treatment at the same time.